Clinical Trial: A Prospective Randomized Controlled Trial Using ctDNA-Based Molecular Residual Disease Detection to Guide the Decision to Forgo Adjuvant Therapy Following Combined Resection of Pelvic Organs in Colorectal Cancer (China)

China, Aug. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective Randomized Controlled Trial Using ctDNA-Based Molecular Residual Disease Detection to Guide the Decision to Forgo Adjuvant Therapy Following Combined Resection of Pelvic Organs in Colorectal Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129903

Registration Time: 2026/08/11

Type: Interventional study

Primary Sponsor: The Second Affiliated Hospital of the Naval Medical University (Shanghai Changzheng Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=321741

Published by HT Digital Content Services with permission from Healt...